The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study

Table 4 Laboratory values before PPI initiation and at 96 weeks of treatment

Inspection item	Standard value	Group	0 week	n	96 week	n	p
Hb (g/dL)	Male: 13.4–17.4 Female: 11.3–14.9	Lansoprazole	14.1 ± 0.17	108	13.9 ± 0.16	105	0.355	a
Hb (g/dL)	Male: 13.4–17.4 Female: 11.3–14.9	Esomeprazole	14.1 ± 0.23	56	13.4 ± 0.27	56	0.001	b
PLT (× 10⁴/μL)	10.0–40.0	Lansoprazole	19.9 ± 0.53	108	18.9 ± 0.47	105	0.185	a
PLT (× 10⁴/μL)	10.0–40.0	Esomeprazole	19.8 ± 0.73	56	20.0 ± 0.73	56	0.326	b
WBC (/μL)	Male: 4100–8500 Female: 3900–7800	Lansoprazole	8223 ± 339	108	5864 ± 152	105	< 0.001	a
WBC (/μL)	Male: 4100–8500 Female: 3900–7800	Esomeprazole	9838 ± 972	56	6130 ± 241	56	< 0.001	b
ALT (U/L)	Male: 10–42 Female: 7–23	Lansoprazole	28.4 ± 1.8	102	21.7 ± 1.1	104	0.017	a
ALT (U/L)	Male: 10–42 Female: 7–23	Esomeprazole	27.6 ± 3.5	55	23.3 ± 1.9	53	0.832	a
Cr (mg/dL)	Male: 0.65–1.07 Female: 0.46–0.79	Lansoprazole	1.07 ± 0.11	109	1.08 ± 0.12	107	0.038	a
Cr (mg/dL)	Male: 0.65–1.07 Female: 0.46–0.79	Esomeprazole	1.24 ± 0.2	56	1.26 ± 0.19	56	0.051	b
Na (mEq/L)	138–145	Lansoprazole	140 ± 0.24	109	140 ± 0.24	107	0.023	a
Na (mEq/L)	138–145	Esomeprazole	140 ± 0.35	55	141 ± 0.30	55	0.031	a
K (mEq/L)	3.6–4.8	Lansoprazole	4.1 ± 0.04	108	4.4 ± 0.04	106	< 0.001	a
K (mEq/L)	3.6–4.8	Esomeprazole	4.1 ± 0.07	55	4.3 ± 0.06	55	0.046	a
Mg (mg/dL)	1.7–2.5	Lansoprazole	2.1 ± 0.03	41	2.1 ± 0.03	51	0.502	a
Mg (mg/dL)	1.7–2.5	Esomeprazole	2.0 ± 0.08	14	2.0 ± 0.06	20	0.845	a
Ca (mg/dL)	8.8–10.1	Lansoprazole	9.3 ± 0.07	68	9.5 ± 0.05	74	0.092	a
Ca (mg/dL)	8.8–10.1	Esomeprazole	9.2 ± 0.07	29	9.3 ± 0.10	30	0.767	a

ISSN: 2055-0294